Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

491
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
491
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

443
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
443
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

763
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
763
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.3K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.3K
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.8K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.8K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

823
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
823

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ARCH-SPIKES: Faculty Development to Deliver High-Stake, Complex Feedback.

Family medicine·2026
Same author

The Priority Updates from the Research Literature (PURLs) Methodology.

Journal of the American Board of Family Medicine : JABFM·2024
Same author

Using Social Media to Teach About and Engage Residents in Evidence-Based Medicine.

Family medicine·2024
Same author

Going (Anti)Viral: Improving HIV and HCV Screening and HPV Vaccination in Primary Care.

Joint Commission journal on quality and patient safety·2024
Same author

Should Metformin Continue as First-Line Pharmacotherapy for Patients With Type 2 Diabetes? Yes: Metformin Is Still the Best Choice.

American family physician·2024
Same author

Priority Updates to the Research Literature (PURLs) Series Now Featured in the <i>JABFM</i>.

Journal of the American Board of Family Medicine : JABFM·2024

Related Experiment Video

Updated: Dec 29, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.2K

PURL: A better approach to preventing active TB?

Sandra Sauereisen1, Gregory Castelli1

  • 1UPMC St. Margaret Family Medicine Residency, Pittsburgh, PA, USA.

The Journal of Family Practice
|February 5, 2020
PubMed
Summary

Nine months of isoniazid prevents latent tuberculosis (TB) infection from becoming active. This study explores if shorter, less toxic treatment options exist for latent TB prevention.

Area of Science:

  • Infectious Diseases
  • Public Health
  • Pharmacology

Background:

  • Latent tuberculosis infection (LTBI) is a significant risk factor for developing active tuberculosis disease.
  • Current standard treatment for LTBI involves a 9-month regimen of isoniazid (INH).
  • Long treatment durations can lead to poor patient adherence and potential toxicity concerns.

Purpose of the Study:

  • To evaluate the efficacy and safety of alternative, shorter treatment regimens for LTBI.
  • To identify potential substitutes for the 9-month isoniazid regimen.
  • To explore options that minimize toxicity while maintaining preventive effects against active TB.

Main Methods:

  • Systematic review of clinical trials comparing shorter LTBI treatment regimens with standard 9-month isoniazid.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.0K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.2K

Related Experiment Videos

Last Updated: Dec 29, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.2K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.0K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.2K
  • Meta-analysis of data on treatment completion rates, incidence of active TB, and adverse events.
  • Assessment of drug toxicity profiles for alternative medications.

    • Main Results:

    • Several shorter regimens, including those with rifampicin or shorter-acting combinations, show comparable efficacy to 9-month isoniazid in preventing active TB.
    • Some alternative regimens demonstrate improved treatment completion rates.
    • Certain shorter regimens may present a different toxicity profile, potentially offering advantages in specific patient populations.

    Conclusions:

    • Shorter treatment durations for LTBI are feasible and effective alternatives to the 9-month isoniazid regimen.
    • The choice of regimen should consider efficacy, safety, tolerability, and patient-specific factors.
    • Further research may refine optimal shorter regimens for global TB control efforts.